These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36726438)

  • 1. Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany.
    Pecoits-Filho R; McCullough K; Muenz D; Quinn CM; Budden J; Golden J; de Arellano AR; Tillmann FP; Duttlinger J; Calice-Silva V; Massy ZA; Bieber B; Robinson BM; Fliser D; Reichel H;
    Clin Kidney J; 2023 Jan; 16(1):176-183. PubMed ID: 36726438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
    Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
    PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.
    Obi Y; Thomas F; Dashputre AA; Goedecke P; Kovesdy CP
    Kidney Med; 2024 Jan; 6(1):100757. PubMed ID: 38192434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world management of hyperkalemia with patiromer among United States Veterans.
    Kovesdy CP; Gosmanova EO; Woods SD; Fogli JJ; Rowan CG; Hansen JL; Sauer BC
    Postgrad Med; 2020 Mar; 132(2):176-183. PubMed ID: 31971043
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials.
    Haller H; Bianchi S; McCafferty K; Arthur S; Quinn CM; Budden J; Weir MR
    Kidney360; 2022 Dec; 3(12):2019-2026. PubMed ID: 36591361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.
    Bushinsky DA; Williams GH; Pitt B; Weir MR; Freeman MW; Garza D; Stasiv Y; Li E; Berman L; Bakris GL
    Kidney Int; 2015 Dec; 88(6):1427-1433. PubMed ID: 26376130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
    Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
    Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world management of chronic and postprandial hyperkalemia in CKD patients treated with patiromer: a single-center retrospective study.
    Riccio E; D'Ercole A; Sannino A; Hamzeh S; De Marco O; Capuano I; Buonanno P; Rizzo M; Pisani A
    J Nephrol; 2024 May; 37(4):1077-1084. PubMed ID: 38319545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing patiromer utilization and associated serum potassium changes in US veterans with prior sodium polystyrene sulfonate exposure.
    Patel S; Pinnell D; Qualls J; Rathod A; Chen W; Boutin S; Woods SD; Kovesdy CP; Tangri N; Sauer BC
    Medicine (Baltimore); 2023 Mar; 102(9):e33134. PubMed ID: 36862858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective.
    Fischer B; Serra A; Telser H
    Adv Ther; 2022 Jun; 39(6):2717-2730. PubMed ID: 35416597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial.
    Weir MR; Rossignol P; Pitt B; Lund LH; Coats AJS; Filippatos G; Perrin A; Waechter S; Budden J; Kosiborod M; Metra M; Boehm M; Ezekowitz JA; Bayes-Genis A; Mentz RJ; Ponikowski P; Senni M; Castro-Montes E; Nicolau JC; Parkhomenko A; Seferovic P; Cohen-Solal A; Anker SD; Butler J
    Am J Nephrol; 2024 Aug; ():1-18. PubMed ID: 39159624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis.
    Coats AJS; Anker SD; Lund LH; Filippatos G; Rossignol P; Pitt B; Weir MR; Kosiborod MN; Metra M; Böhm M; Ezekowitz JA; Bayes-Genis A; Mentz RJ; Ponikowski P; Senni M; Cleland JGF; Goudev A; Khintibidze I; Lindenfeld J; Merkely B; Waechter S; Budden J; Perrin A; Butler J
    JACC Heart Fail; 2024 Sep; ():. PubMed ID: 39340493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials.
    Bushinsky DA; Budden JJ; Kalra PA; Yuan J; Quinn CM; Epstein M
    Am J Kidney Dis; 2023 Jul; 82(1):97-104. PubMed ID: 36965827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.